Cargando…

Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study

BACKGROUND: Clinical evidence demonstrating a longitudinal association between prescribed medications and sarcopenia onset is lacking. We investigated the association of polypharmacy (the use of five or more medications) and potentially inappropriate medications (PIMs) with sarcopenia risk in commun...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Tomoki, Akishita, Masahiro, Kojima, Taro, Son, Bo-Kyung, Iijima, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294366/
https://www.ncbi.nlm.nih.gov/pubmed/37365526
http://dx.doi.org/10.1186/s12877-023-04012-y
_version_ 1785063180342394880
author Tanaka, Tomoki
Akishita, Masahiro
Kojima, Taro
Son, Bo-Kyung
Iijima, Katsuya
author_facet Tanaka, Tomoki
Akishita, Masahiro
Kojima, Taro
Son, Bo-Kyung
Iijima, Katsuya
author_sort Tanaka, Tomoki
collection PubMed
description BACKGROUND: Clinical evidence demonstrating a longitudinal association between prescribed medications and sarcopenia onset is lacking. We investigated the association of polypharmacy (the use of five or more medications) and potentially inappropriate medications (PIMs) with sarcopenia risk in community-dwelling older adults. METHODS: In this longitudinal population-based cohort study, 2,044 older residents with no long-term care needs were randomly selected from a community in Kashiwa, Japan. Baseline data collection was conducted in 2012, with follow-ups in 2013, 2014, 2016, 2018, and 2021. Prescribed medications and PIMs (drugs listed in the Screening Tool for Older Person’s Appropriate Prescriptions for the Japanese or potentially muscle-wasting drugs) were identified through interviews. New-onset sarcopenia was identified according to the 2019 criteria of the Asian Working Group for Sarcopenia over a 9-year period and analyzed. We used Cox proportional hazards models to test the longitudinal association of prescribed medications with sarcopenia onset. RESULTS: Of the 1,549 participants without sarcopenia at baseline (mean age, 72.5 ± 5.5 years; 49.1% women; median and interquartile range, 6.0 [4.0–9.0] years), 230 experienced new-onset sarcopenia during the follow-up. After adjusting for confounders, polypharmacy combined with PIM use was strongly associated with new-onset sarcopenia (adjusted hazard ratio, 2.35; 95% confidence interval, 1.58–3.51; P < 0.001). No significant associations were observed for either PIM use or polypharmacy alone. CONCLUSIONS: Polypharmacy combined with PIM use, but not polypharmacy alone, was associated with an increased risk of new-onset sarcopenia over the 9-year follow-up period among community-dwelling older adults. Limiting polypharmacy and imposing the prescription of appropriate medications may facilitate sarcopenia prevention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-04012-y.
format Online
Article
Text
id pubmed-10294366
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102943662023-06-28 Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study Tanaka, Tomoki Akishita, Masahiro Kojima, Taro Son, Bo-Kyung Iijima, Katsuya BMC Geriatr Research BACKGROUND: Clinical evidence demonstrating a longitudinal association between prescribed medications and sarcopenia onset is lacking. We investigated the association of polypharmacy (the use of five or more medications) and potentially inappropriate medications (PIMs) with sarcopenia risk in community-dwelling older adults. METHODS: In this longitudinal population-based cohort study, 2,044 older residents with no long-term care needs were randomly selected from a community in Kashiwa, Japan. Baseline data collection was conducted in 2012, with follow-ups in 2013, 2014, 2016, 2018, and 2021. Prescribed medications and PIMs (drugs listed in the Screening Tool for Older Person’s Appropriate Prescriptions for the Japanese or potentially muscle-wasting drugs) were identified through interviews. New-onset sarcopenia was identified according to the 2019 criteria of the Asian Working Group for Sarcopenia over a 9-year period and analyzed. We used Cox proportional hazards models to test the longitudinal association of prescribed medications with sarcopenia onset. RESULTS: Of the 1,549 participants without sarcopenia at baseline (mean age, 72.5 ± 5.5 years; 49.1% women; median and interquartile range, 6.0 [4.0–9.0] years), 230 experienced new-onset sarcopenia during the follow-up. After adjusting for confounders, polypharmacy combined with PIM use was strongly associated with new-onset sarcopenia (adjusted hazard ratio, 2.35; 95% confidence interval, 1.58–3.51; P < 0.001). No significant associations were observed for either PIM use or polypharmacy alone. CONCLUSIONS: Polypharmacy combined with PIM use, but not polypharmacy alone, was associated with an increased risk of new-onset sarcopenia over the 9-year follow-up period among community-dwelling older adults. Limiting polypharmacy and imposing the prescription of appropriate medications may facilitate sarcopenia prevention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-04012-y. BioMed Central 2023-06-26 /pmc/articles/PMC10294366/ /pubmed/37365526 http://dx.doi.org/10.1186/s12877-023-04012-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tanaka, Tomoki
Akishita, Masahiro
Kojima, Taro
Son, Bo-Kyung
Iijima, Katsuya
Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title_full Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title_fullStr Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title_full_unstemmed Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title_short Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study
title_sort polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling japanese older adults: a 9-year kashiwa cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294366/
https://www.ncbi.nlm.nih.gov/pubmed/37365526
http://dx.doi.org/10.1186/s12877-023-04012-y
work_keys_str_mv AT tanakatomoki polypharmacywithpotentiallyinappropriatemedicationsasariskfactorofnewonsetsarcopeniaamongcommunitydwellingjapaneseolderadultsa9yearkashiwacohortstudy
AT akishitamasahiro polypharmacywithpotentiallyinappropriatemedicationsasariskfactorofnewonsetsarcopeniaamongcommunitydwellingjapaneseolderadultsa9yearkashiwacohortstudy
AT kojimataro polypharmacywithpotentiallyinappropriatemedicationsasariskfactorofnewonsetsarcopeniaamongcommunitydwellingjapaneseolderadultsa9yearkashiwacohortstudy
AT sonbokyung polypharmacywithpotentiallyinappropriatemedicationsasariskfactorofnewonsetsarcopeniaamongcommunitydwellingjapaneseolderadultsa9yearkashiwacohortstudy
AT iijimakatsuya polypharmacywithpotentiallyinappropriatemedicationsasariskfactorofnewonsetsarcopeniaamongcommunitydwellingjapaneseolderadultsa9yearkashiwacohortstudy